[go: up one dir, main page]

PE20120012A1 - Sales de fingolimod - Google Patents

Sales de fingolimod

Info

Publication number
PE20120012A1
PE20120012A1 PE2011000987A PE2011000987A PE20120012A1 PE 20120012 A1 PE20120012 A1 PE 20120012A1 PE 2011000987 A PE2011000987 A PE 2011000987A PE 2011000987 A PE2011000987 A PE 2011000987A PE 20120012 A1 PE20120012 A1 PE 20120012A1
Authority
PE
Peru
Prior art keywords
salt
theta
peaks
degrees
approximately
Prior art date
Application number
PE2011000987A
Other languages
English (en)
Inventor
Michael Mutz
Guido Jordine
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42062355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120012(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20120012A1 publication Critical patent/PE20120012A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/122—Propionic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/08—Malonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE A UNA SAL DE 2-AMINO-2-(2-(4-OCTIL-FENIL)-ETIL)-PROPANO-1,3-DIOL (FTY720) SELECCIONADA DE LAS SALES DE TARTRATO, LACTATO, BENZOATO, SUCCINATO, ENTRE OTROS, DONDE: LA SAL DE TARTRATO ESTA CARACTERIZADA POR UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X CON PICOS A APROXIMADAMENTE 3.1, 19.3, 21.7, 9.6, 17.2, 6.4, 22.6 Y 20.2 GRADOS 2-THETA; LA SAL DE LACTATO ESTA CARACTERIZADA POR UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X CON PICOS A APROXIMADAMENTE 4.3, 8.7, 20.8, 13.1, 10.3, 18.8, 8.1, 21.6, 21.9 Y 19.6 GRADOS 2-THETA; LA SAL DE BENZOATO ESTA CARACTERIZADA POR UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X CON PICOS A APROXIMADAMENTE 3.7, 7.5, 18.7, 19.8, 15.2, 19.4, 19.9, 6.0 Y 21.9 GRADOS 2-THETA; LA SAL DE SUCCINATO ESTA CARACTERIZADA POR UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X CON PICOS A APROXIMADAMENTE3.2, 19.8, 20.7, 23.3, 26.2, 9.8, 19.4, 24.5, 33.4, 26.6 Y 22.6 GRADOS 2-THETA. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHA SAL SE ENCUENTRA EN FORMA CRISTALINA SUSTANCIALMENTE PURA SIENDO UTIL COMO INMUNOSUPRESOR EN EL TRATAMIENTO Y/O PREVENCION DE ENFERMEDADES AUTOINMUNES
PE2011000987A 2008-11-11 2009-11-10 Sales de fingolimod PE20120012A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08168862 2008-11-11

Publications (1)

Publication Number Publication Date
PE20120012A1 true PE20120012A1 (es) 2012-02-02

Family

ID=42062355

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000987A PE20120012A1 (es) 2008-11-11 2009-11-10 Sales de fingolimod

Country Status (20)

Country Link
US (2) US8680146B2 (es)
EP (1) EP2358660A2 (es)
JP (2) JP2012508215A (es)
KR (1) KR20110086142A (es)
CN (2) CN105198760A (es)
AU (1) AU2009315735B2 (es)
BR (1) BRPI0921533A2 (es)
CA (1) CA2741974A1 (es)
CL (1) CL2011001041A1 (es)
CO (1) CO6382154A2 (es)
EC (1) ECSP11011121A (es)
IL (1) IL212073A0 (es)
MA (1) MA32877B1 (es)
MX (1) MX2011004924A (es)
NZ (1) NZ591999A (es)
PE (1) PE20120012A1 (es)
RU (1) RU2543621C2 (es)
TN (1) TN2011000187A1 (es)
WO (1) WO2010055027A2 (es)
ZA (1) ZA201102272B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393768T3 (es) 2005-05-26 2012-12-27 Neuron Systems, Inc Derivado de quinolina para el tratamiento de enfermedades retinianas
BRPI0921533A2 (pt) * 2008-11-11 2016-01-12 Novartis Ag composto orgânicos
EP2456752A2 (en) * 2009-07-24 2012-05-30 ratiopharm GmbH Process for producing fingolimod salts
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
PL2632889T3 (pl) 2010-10-28 2019-04-30 Mapi Pharma Ltd Związki pośrednie i sposób wytwarzania fingolimodu
WO2012071524A1 (en) 2010-11-24 2012-05-31 Ratiopharm Gmbh Arylsulfonate salts of fingolimod and processes for preparation thereof
EP2505589A1 (en) 2011-04-01 2012-10-03 Johann Wolfgang Goethe-Universität Frankfurt am Main Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
CN102887829B (zh) * 2012-09-05 2014-07-02 中国科学院上海药物研究所 芬戈莫德粘酸盐及其晶体的制备方法和用途
HK1217439A1 (zh) 2013-01-23 2017-01-13 Aldeyra Therapeutics, Inc. 与毒性醛相关的疾病和治疗
EP2964210B1 (en) 2013-03-05 2023-10-04 Biocon Limited A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
US10675254B2 (en) 2013-10-11 2020-06-09 Teikoku Seiyaku Co., Ltd. Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
EP3054933A4 (en) 2013-10-11 2017-03-15 Teikoku Pharma USA, Inc. Topical sphingosine-1-phosphate receptor agonist formulations and methods of using the same
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016118515A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
MX2018013472A (es) 2016-05-09 2019-02-28 Aldeyra Therapeutics Inc Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares.
MX385269B (es) 2016-05-31 2025-03-14 Taiho Pharmaceutical Co Ltd Compuesto de sulfonamida o sal del mismo.
RU2627691C1 (ru) * 2016-07-06 2017-08-10 Олег Ростиславович Михайлов Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе
AU2018348174A1 (en) 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
TWI762743B (zh) 2017-11-29 2022-05-01 日商大鵬藥品工業股份有限公司 磺醯胺化合物及其用途
AU2019293260A1 (en) * 2018-06-29 2021-01-07 Forma Therapeutics, Inc. Salts of (S)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl)(cyclopropyl)methanone and solid forms thereof
AU2019319740A1 (en) 2018-08-06 2021-03-25 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
MX2022005014A (es) 2019-10-31 2022-05-16 Idorsia Pharmaceuticals Ltd Combinacion de un antagonista de cxcr7 con un modulador del receptor s1p1.
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof
JP2024521882A (ja) * 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2579602B2 (ja) 1992-10-21 1997-02-05 吉富製薬株式会社 ２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
ECSP951461A (es) 1995-06-07 1998-04-07 SINTESIS DE 3- {4-(2- AMINOETOXI) BENZOIL]-2-ARIL-6- HIDROXIBENZO {b] TIOFENOS (CASO X- 9295B)
ECSP972265A (es) 1997-09-23 1998-11-30 Dihidrato de d-olanzapina
FR2785607B1 (fr) 1998-11-09 2001-02-09 Rhodia Chimie Sa Procede de preparation de tris(ether-amine)
ES2644413T3 (es) * 1998-11-11 2017-11-28 Novartis Ag Producción de 2-amino-2-[2-(4-alquil-fenil)etil]propano-1,3-dioles
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
RU2003136730A (ru) * 2001-06-08 2005-05-20 Новартис АГ (CH) Лечение или профилактика отторжения инсулин-продуцирующего клеточного трансплантата
PT1505959E (pt) 2002-05-16 2009-02-05 Novartis Ag Utilização de agentes de ligação do receptor edg em cancro
GB0217152D0 (en) * 2002-07-24 2002-09-04 Novartis Ag Organic compounds
NZ592339A (en) 2003-04-08 2012-09-28 Novartis Ag Solid pharmaceutical compositions of S1P receptor agonist with sugar alcohol
GT200600350A (es) 2005-08-09 2007-03-28 Formulaciones líquidas
RU2008116578A (ru) * 2005-09-30 2009-11-10 Новартис АГ (CH) Применение ингибиторов dpp-iv для лечения аутоиммунных заболеваний и отторжения трансплантата
ES2414205T3 (es) * 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
WO2009100116A1 (en) * 2008-02-04 2009-08-13 Medical College Of Georgia Research Institute Oligodendrocyte precursor cell composition and methods of use
BRPI0921533A2 (pt) * 2008-11-11 2016-01-12 Novartis Ag composto orgânicos

Also Published As

Publication number Publication date
WO2010055027A3 (en) 2010-08-19
AU2009315735A1 (en) 2010-05-20
US20140235722A1 (en) 2014-08-21
CN105198760A (zh) 2015-12-30
AU2009315735B2 (en) 2013-01-10
CL2011001041A1 (es) 2011-10-07
US8680146B2 (en) 2014-03-25
MX2011004924A (es) 2011-05-30
JP2015178503A (ja) 2015-10-08
ZA201102272B (en) 2011-12-28
RU2011123365A (ru) 2012-12-20
EP2358660A2 (en) 2011-08-24
NZ591999A (en) 2013-06-28
CN102256933A (zh) 2011-11-23
WO2010055027A2 (en) 2010-05-20
KR20110086142A (ko) 2011-07-27
MA32877B1 (fr) 2011-12-01
TN2011000187A1 (en) 2012-12-17
CA2741974A1 (en) 2010-05-20
US20110218248A1 (en) 2011-09-08
RU2543621C2 (ru) 2015-03-10
IL212073A0 (en) 2011-06-30
JP2012508215A (ja) 2012-04-05
BRPI0921533A2 (pt) 2016-01-12
ECSP11011121A (es) 2011-07-29
CO6382154A2 (es) 2012-02-15

Similar Documents

Publication Publication Date Title
PE20120012A1 (es) Sales de fingolimod
CY1124208T1 (el) Αλατα η συγκρυσταλλοι της 3-(3-διμεθυλαμινο-1-αιθυλο-2-μεθυλο-προπυλο)-φαινολης
JP2013525444A5 (es)
RU2015111229A (ru) Кристаллические формы гидрохлорида финголимода
DOP2014000064A (es) Compuestos 1-arilcarbonil-4-oxi-piperidina útiles para el tratamiento de enfermedades neurodegenerativas
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
PE20120989A1 (es) Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo
BR112014005389A8 (pt) Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
CL2014003475A1 (es) Forma c cristalina de acido obeticolico; proceso de preparacion de la forma 1 de acido obeticolico a partir de la forma c cristalina; composicion farmaceutica que comprende a una forma cristalina de acido obeticolico, util para el tratamiento o prevencion de una enfermedad hepatica colestasica, hepatopatia alcoholica y enfermedades cardiovasculares tal como aterosclerosis, entre otras.
UY32030A (es) "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
UY33317A (es) Nuevos derivados de pirazol
ECSP12012125A (es) Ariltriazolonas ligadas a bisarilo y su uso
CL2014000441A1 (es) Una entidad quimica que comprende el compuesto sulfamato de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-cloro-2-metoxi-2,3-dihidro-1h-inden-1-il]amino}pirimidin-4-il)oxi]-2-hidroxiciclopentil}metilo; inhibidor de la activacion de la enzima nedd-8; forma cristalina i; profarmaco del compuesto; composicion farmaceutica; un metodo para tratar el cancer.
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
PE20141113A1 (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
PE20140337A1 (es) Nuevas formas cristalinas de la sal sodica del acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclhexil)-acetico
PE20110393A1 (es) Nuevos compuestos adecuados como precursores de compuestos que son utiles para obtener imagenes de depositos amiloides
NZ601920A (en) New crystalline form of a cyclopropyl benzamide derivative
JP2013521297A5 (es)
PE20081797A1 (es) Nueva forma de dosificacion
AR074592A1 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina, procesos e intermediario para su sintesis y su uso en el tratamiento de una enfermedad mediada por un antagonista de los receptores mu opioides.
AR080150A1 (es) Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento del trastorno obsesivo compulsivo (toc)
AR064215A1 (es) Proceso para obtener el r-enantiomero de salbutamol
ECSP088088A (es) Maleato de 3-[2-(dimetilamino)metil-(ciclohex-1-il)]fenol y sus formas cristalinas

Legal Events

Date Code Title Description
FC Refusal